Recruiting PHASE1 INTERVENTIONAL 1-arm
NCT07233642
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
Study of Ultra-Fast Autologous CD19-targeted Chimeric Antigen Receptor T (CAR- T) Therapy for Refractory Systemic Lupus Erythematosus
Sponsor: The Children's Hospital of Zhejiang University School of Medicine
Conditions
Systemic Lupus Erythematosus
Interventions
CD19 CAR-T cells
Updated 1 time since 2025 Last updated: Nov 16, 2025 Started: Nov 30, 2025 Primary completion: May 31, 2026 Completion: Sep 30, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE1 trial investigates Systemic Lupus Erythematosus and is currently actively recruiting participants. The Children's Hospital of Zhejiang University School of Medicine leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
1 version recorded Recruiting — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- The Children's Hospital of Zhejiang University School of Medicine
Data source: The Children's Hospital of Zhejiang University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .